BREATHE Life Sciences has been awarded a Good Manufacturing Practice (GMP) licence for the production of medical cannabis.
The licence also encompasses the manufacturing of psilocybin & MDMA, marking a first in Australia for GMP certification of the substances.
The TGA has granted Breathe the GMP licence authorising the company to manufacture MDMA and psilocybin active pharmaceutical ingredients as well as final dose capsules.
Intended for supply to authorised prescribers and clinical trials, the products set a new precedent in the treatments available for mental health disorders, according to a company statement.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Feb 24
